ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • 2026 ACR/ARP PRSYM
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "risk factors"

  • Abstract Number: 0744 • ACR Convergence 2024

    Cerebrovascular Accidents (CVA) in Giant Cell Arteritis: Identification of Predictive Factors from the ARTESER Registry

    Adrián Martín-Gutiérrez1, Juan Molina-Collada2, Marta Domínguez-Álvaro3, Rafael Benito Melero-Gonzalez4, Elisa Fernández-Fernández:5, Maite Silva-Diaz6, Jesús Alejandro Valero7, Ismael Gonzalez8, Julio Sánchez-Martín9, Javier Narvaez-García10, Itziar Calvo11, Vicente Aldasoro12, lydia Abasolo Alcazar13, ALBERTO MARIANO RUIZ ROMAN14, Javier Loricera15, Santos Castañeda16, Clara Molina Almela17, María Alcalde Villar:18, Antonio Juan-Mas19 and Ricardo Blanco-Alonso20, 1Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, 2Hospital General Universitario Gregorio Marañón, Madrid, Spain, 3Sociedad Española de Reumatología, Madrid, Spain, 4CHU Ourense, O Carballino, Spain, 5La Paz University Hospital, Alcalá de Henares, Madrid, Spain, 6Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, 7Hospital Universitario Donosti. Donostia, Spain, Donosti, Spain, 8Complejo Asistencial Universitario de Leon, León, Spain, 9Hospital Universitario 12 de Octubre, Madrid, Spain, 10Hospital Universitario de Bellvitge, Barcelona, Spain, 11Hospital Universitario de Basurto, Bilbao, Spain, 12Hospital Universitario de Navarra, Pamplona, Spain, 13IdISSC. HCSC, Madrid, Spain, 14Hospital Universitario Juan Ramón Jiménez, Huelva, Spain, 15Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 16Hospital Universitario de la Princesa, Madrid, Spain, 17Consorcio Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, 18Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Spain, 19Rheumatology Department, Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Cantabria, Spain, 20Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Giant cell arteritis (GCA) is the most common form of systemic vasculitis in the elderly and involves the large and medium-sized vessels. Cerebrovascular accidents…
  • Abstract Number: 1106 • ACR Convergence 2024

    Factors Associated with Relapse in Giant Cell Arteritis Treated with Tocilizumab. Multicenter Open-label Study of 407 Patients

    Adrián Martín-Gutiérrez1, Javier Loricera2, Carmen Secada Gómez3, Clara Moriano4, Javier Narvaez-García5, Vicente Aldasoro6, Olga Maíz Alonso7, Iñigo Hernández-Rodríguez8, Paloma Vela-Casasempere9, Susana Romero Yuste10, Eugenio De Miguel11, Eva Galindez-Agirregoikoa12, Jesus C. Fernandez-López13, ivan Ferraz-Amaro14, Julio Sánchez-Martín15, José Luis Callejas16, Patricia Moya Albarado17, Cristina Campos Fernández18, Fernando Lopez-Gutierrez19, Santos Castañeda20 and Ricardo Blanco-Alonso21, and the Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group, 1Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 4Hospital León, LEON, Spain, 5Hospital Universitario de Bellvitge, Barcelona, Spain, 6Hospital Universitario de Navarra, Pamplona, Spain, 73Hospital Universitario de Donosti, San Sebastian, Spain, San Sebastian, Pais Vasco, Spain, 8Complejo Hospitalario Universitario de Vigo, Vigo, Spain, 9Hospital General Universitario Alicante, Alicante, Spain, 10Department of Rheumatology, University Hospital Complex of Pontevedra, Pontevedra, Spain, 11Hospital Universitario La Paz, Madrid, Spain, 12BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, 1311Rheumatology, Hospital Universitario Juan Canalejo, A Coruña, Spain., A Coruña, Spain, 14Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, 15Hospital Universitario 12 de Octubre, Madrid, Spain, 16Systemic Autoimmune Diseases Unit, Hospital Clinico San Cecilio, Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain, 17Hospital de San Pau, Barcelona, Spain, 18Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain, 19Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, 20Hospital Universitario de la Princesa, Madrid, Spain, 21Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Tocilizumab (TCZ) is the only biological drug approved for the treatment of giant cell arteritis (GCA). Clinical trials were performed with intravenous (IV) and…
  • Abstract Number: 1901 • ACR Convergence 2024

    Venous Thromboembolism Risk Is Consistently Increased in People with Rheumatoid Arthritis Across Different Ages, Sexes and Obesity Status: United Kingdom Population Based Study

    James Galloway1, Victoria Basey2, Michael Mclean2, Simon de Lusignan3 and Maya H. Buch4, 1Centre for Rheumatic Diseases, King's College London, London, United Kingdom, 2Pfizer UK, Tadworth, United Kingdom, 3Royal College of General Practitioners Research and Surveillance Centre, Oxford, United Kingdom, 4Division of Musculoskeletal & Dermatological Sciences, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom

    Background/Purpose: Risk of venous thromboembolism (VTE) is increased in people with rheumatoid arthritis (RA) when compared to the general population, but the variation of this…
  • Abstract Number: 2566 • ACR Convergence 2024

    Detrimental Effects of Proton Pump Inhibitors on Bone Mineral Density Are Not Mediated by Changes in Serum Calcium or Parathyroid Hormone in Patients with Inflammatory Rheumatic Diseases: A Cross-sectional Study

    andriko Palmowski1, Zhivana Boydzhieva2, Paula Hoff3, Sandra Hermann3, burkhard Muche3, David Simon4, Gerhard Krönke3, Edgar Wiebe5 and FRANK HARTMUT DR. BUTTGEREIT5, 1Charité - Universittsmedizin Berlin, Berlin, Germany, 2Charité Universittsmedizin, Berlin, Germany, 3Rheumatology, Charité, Berlin, Germany, 4Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany/ Department of Internal Medicine 3, University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany/Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Berlin, Germany, 5Charité University Medicine Berlin, Berlin, Germany

    Background/Purpose: In a previous study, we found daily proton pump inhibitor (PPI) intake to be associated with decreased bone mineral density in patients with inflammatory…
  • Abstract Number: 0134 • ACR Convergence 2023

    Stressful Life Events in the Year Prior to Their Diagnosis Are Associated with Adult and Pediatric Systemic Rheumatic Diseases

    Iazsmin Bauer Ventura1, Maya Goldberg2, Adam Schiffenbauer3, Min Shi4, Rita Volochayev5, Sharon H. Jackson6, Anna Jansen5, Nastaran Bayat7, Christine Parks8, Clarice R. Weinberg4, Angelo Picardi9, Frederick Miller10 and Lisa Rider3, 1University of Chicago, Chicago, IL, 2National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, 3NIEHS, NIH, Bethesda, MD, 4Biostatitstics & Computational Biology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, 5Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, 6National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, 7Social Scientific Systems, DLH Holdings Corp, Silver Spring, MD, 8Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, 9Centre for Behavioral Sciences and Mental Health, Italian National Institute of Health, Rome, Italy, 10NIH, NIEHS, Chapel Hill, NC

    Background/Purpose: Systemic rheumatic diseases (SRDs) are complex multi-organ immune-mediated disorders that arise from the interaction of environmental exposures in genetically predisposed individuals. Stressful life events…
  • Abstract Number: 0659 • ACR Convergence 2023

    Cigarette Exposure in Systemic Sclerosis: Impact on Autoantibody Expression and Disease Manifestations: Analysis of the EUSTAR Cohort

    Jacopo Ciaffi1, Sophie Liem2, Saad Ahmed2, Eva Hoekstra2, Piotr Wiland3, Tatsuya Atsuma4, Gabriella Szucs5, Alexandra Balbir-Gurman6, Laszlo Czirjak7, Elisabetta Zanatta8, Ina Koetter9, Joerg Henes10, marco Matucci Cerinic11, Paolo Airò12, Francesco Ursini13, Thomas Huizinga2 and Jeska de Vries-Bouwstra2, 1IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, 2Leiden University Medical Center, Leiden, Netherlands, 3Wroclaw University of Medicine, Wroclaw, Poland, 4Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, 5University of Debrecen, Department of Rheumatology, Debrecen, Hungary, 6Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, 7Dept. Rheumatol Immunol, Medical School, university of Pecs, Pecs, Hungary, 8Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padova, Padua, Italy, 9University Hospital Eppendorf, Prisdorf, Germany, 10University Hospital Tuebingen, Tuebingen, Germany, 11Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, 12Spedali Civili di Brescia, Scleroderma UNIT, UOC Reumatologia ed Immunologia Clinica, Piazzale Spedali Civili 1, 25123, Brescia, Italy, 13IRCCS Istituto Ortopedico Rizzoli, Bologna, Netherlands

    Background/Purpose: In rheumatoid arthritis, cigarette smoking confers a risk for anti-CCP positive disease and the risk further increases in smokers carrying specific HLA DRB1-variants. These…
  • Abstract Number: 1281 • ACR Convergence 2023

    Risk of Cancer in Patients with Rheumatoid Arthritis Under Tocilizumab: Data from the French National Registry REGATE

    JACQUES MOREL1, Amélie Wetzman2, Daniel Wendling3, Martin Soubrier4, Olivier Roth5, Jacques-Eric Gottenberg6, Philippe Goupille7, Xavier Mariette8 and Cedric Lukas9, 1Protocole thérapeutique immuno-rhumatologie, Montpellier, France, 2CHU and University of Montpellier, Narbonne, France, 3Besançon University Hospital, Besançon, France, 4Gabriel-Montpied Hospital, Clermont-ferrand, France, 5Saint Joseph Hospital, Marseille, France, 6Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, 7CHU and University of Tours, Tours, France, 8Université Paris-Saclay, Le Kremlin-Bicêtre, France, 9CHU Montpellier, Montpellier, France

    Background/Purpose: Our study aimed to estimate the incidence and risk factors of cancer among rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ) and followed for…
  • Abstract Number: 2021 • ACR Convergence 2023

    Beliefs, Attitudes, and Preferences of Patients with Rheumatoid Arthritis (RA) and Concomitant Cancer with Respect to RA Therapy

    Juan Ruiz1, Sheneze Madramootoo2, Maria A. Lopez-Olivo1, Namrata Singh3 and Maria Suarez-Almazor4, 1The University of Texas, MD Anderson Cancer Center, Houston, TX, 2The University of Texas MD Anderson Cancer Center, Houston, TX, 3University of Washington, Bellevue, WA, 4MD Anderson Cancer Center, Houston, TX

    Background/Purpose: Treatment of rheumatoid arthritis (RA) in patients with cancer could potentially result in poor cancer outcomes because of immunosuppression. Adequate data for shared decision-making…
  • Abstract Number: 2521 • ACR Convergence 2023

    Understanding Age as a Risk Factor for Complications After Total Knee Arthroplasty: What Can We Learn from Machine Learning?

    Bella Mehta1, Yi Yiyuan2, Chloe Heiting3, Kaylee Ho2, Susan Goodman3, Peter Sculco3, Fei Wang2, Rich Caruana4, Peter cram5 and Said Ibrahim6, 1Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 2Weill Cornell Medicine, New York, NY, 3Hospital for Special Surgery, New York, NY, 4Microsoft, Redmond, WA, 5The University of Texas Medical Branch, Galveston, TX, 6Northwell Health, New Hyde Park, NY

    Background/Purpose: Rates of total knee arthroplasty (TKA) in the United Stateshave risen, coupled with increasing demand for TKAs in younger patients.1Althoughrates of postoperative complications in…
  • Abstract Number: 0136 • ACR Convergence 2023

    The Prevalence and Risk Factors of Retinal Toxicity Associated with Long-term Hydroxychloroquine Use

    Sophie Do, Jennifer Du, Jaejin An, Jim Wang and Antony Lin, Kaiser SCAL, Fontana, CA

    Background/Purpose: Hydroxychloroquine (HCQ) is commonly used for the treatment of various autoimmune diseases. The medication is generally well-tolerated. However, long-term use after 5 years may…
  • Abstract Number: 0660 • ACR Convergence 2023

    Cigarette Smoking Increases the Risk of All-Cause Mortality in Male Patients with Systemic Sclerosis: An Analysis of the EUSTAR Cohort

    Jacopo Ciaffi1, Sophie Liem2, Saad Ahmed2, Eva Hoekstra2, Piotr Wiland3, Tatsuya Atsuma4, Gabriella Szucs5, Alexandra Balbir-Gurman6, Laszlo Czirjak7, Elisabetta Zanatta8, Ina Koetter9, Joerg Henes10, marco Matucci Cerinic11, Paolo Airò12, Francesco Ursini13, Thomas Huizinga2 and Jeska de Vries-Bouwstra2, 1IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, 2Leiden University Medical Center, Leiden, Netherlands, 3Wroclaw University of Medicine, Wroclaw, Poland, 4Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, 5University of Debrecen, Department of Rheumatology, Debrecen, Hungary, 6Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, 7Dept. Rheumatol Immunol, Medical School, university of Pecs, Pecs, Hungary, 8Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padova, Padua, Italy, 9University Hospital Eppendorf, Prisdorf, Germany, 10University Hospital Tuebingen, Tuebingen, Germany, 11Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, 12Spedali Civili di Brescia, Scleroderma UNIT, UOC Reumatologia ed Immunologia Clinica, Piazzale Spedali Civili 1, 25123, Brescia, Italy, 13IRCCS Istituto Ortopedico Rizzoli, Bologna, Netherlands

    Background/Purpose: Cigarette smoking is an established risk factor for mortality in the general population but, in systemic sclerosis (SSc), evidence about the role of smoking…
  • Abstract Number: 1291 • ACR Convergence 2023

    Risk Factors for Major Adverse Cardiovascular Events and Malignancies in Patients with Rheumatoid Arthritis in a Real-World Setting in Japan

    Toshitaka Hirano1, Naonobu Sugiyama2, Masato Hoshi1, Joo-Young Jo3, Kichul Shin4 and Kunihiro Yamaoka5, 1Pfizer Japan Inc, Tokyo, Japan, 2Pfizer Japan Inc, Japan, Japan, 3Pfizer Pharmaceuticals Korea Ltd, Seoul, South Korea, 4Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, South Korea, 5Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan

    Background/Purpose: Patients (pts) with RA are at an increased risk of major adverse cardiovascular events (MACE) and malignancies vs the general population.1,2 However, risk factors…
  • Abstract Number: 2052 • ACR Convergence 2023

    Risk Factors for Hospitalization for SARS-CoV-2 in Pediatric Patients with Rheumatic Diseases: A Systematic Review and Meta-analysis

    Qianzi Zhao1, Beth Wallace2, Lawrence Jung3 and Tova Ronis4, 1Trinity Health Ann Arbor, Ann Arbor, MI, 2Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, 3Jung Medical, Cedar Falls, IA, 4Children's National Hospital, Chevy Chase, MD

    Background/Purpose: Among adults who develop SARS-CoV-2 infection, those with rheumatic diseases (RDs) have similar hospitalization rates compared to those without RDs. Similar comparisons are lacking…
  • Abstract Number: 2530 • ACR Convergence 2023

    Risk Evaluation of Osteoporotic Fractures Following Lung Transplantation (LT): A Retrospective Cohort Study Conducted at an International Transplant Center

    Sarah Keller1, Adil Vural2, Jennifer Varley2, Komal Mushtaq2, Walaa Abu Alya3, Neel Tapryal2, Hassan Shaheen3, Marie Budev2, Abby Abelson2 and Chad Deal1, 1Cleveland Clinic Foundation, Cleveland, OH, 2Cleveland Clinic, Cleveland, OH, 3Cleveland Clinic Fairview Hospital, Cleveland, OH

    Background/Purpose: Osteoporotic fractures are a well-known complication in LT recipients, significantly impacting their quality of life. Specific risk factors for these fractures in LT recipients…
  • Abstract Number: 0176 • ACR Convergence 2023

    Impact of Social Determinants of Health Factors on Medication Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus

    Jean Park, W. Cliff Rutter, Elisea Avalos-Reyes, Chen Liu, Will Cavers, Dorothea Verbrugge and Kjel Johnson, CVS Health, Woonsocket, RI

    Background/Purpose: Social determinants of health (SDOH) have a significant impact on the health outcomes of many chronic conditions, including rheumatoid arthritis (RA), psoriatic arthritis (PsA)…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 28
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology